Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Fernando BrilMichael J McPhaulMichael P CaulfieldVirginia C ClarkConsuelo Soldevilla-PicoRoberto J Firpi-MorellJinping LaiCarmen H TongCharles M RowlandKenneth Cusi

Published in: Diabetes care (2019)

Performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of NASH or advanced fibrosis was suboptimal in patients with T2DM. Combination of multiple tests may provide an alternative to minimize the need for liver biopsies to detect fibrosis in these patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
type diabetes
patient reported outcomes
adipose tissue
skeletal muscle
weight loss